Long‐term survival estimates for imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia

Abstract

Assuming the relation between CCyR and survival with interferon-alpha holds for imatinib, higher CCyR rates with imatinib therapy will result in an estimated 6.23 life-years gained compared with treatment with IFN+LDAC.